Antiemetic

Playful Puppy Nearly Dies After Ingesting Cigarette

Retrieved on: 
Wednesday, November 1, 2023
American Cancer Society, Liver injury, Xylitol, Shih Tzu, Poisoning, Seizure, Heart, Health, Vomiting, Life, Human, Family, Toxicology, Great American Smokeout, Smoke, Pet, CNS, Observation, Antiemetic, Tobacco, Hypoglycemia, Hypotension, Hypertension, Risk, Methocarbamol, Gizmo, Tachypnea, Animal, Lethargy, Tremor, Ataxia, Contra body movement, Agitation, Depression, Anticonvulsant, Nicotine, Tachycardia, Heated tobacco product

MINNEAPOLIS, Nov. 1, 2023 /PRNewswire/ --  Arizona dust storms can be dangerous, but one recent gust carried something deadly into Corinna Lopez's backyard – a half-smoked cigarette and butt. Yes, we know cigarettes can be deadly to humans, but in this case the victim was canine. After her four-pound Shih Tzu puppy named Gizmo ingested part of the cigarette, he lost full control of his body movements, vomited and had a seizure.

Key Points: 
  • After her four-pound Shih Tzu puppy named Gizmo ingested part of the cigarette, he lost full control of his body movements, vomited and had a seizure.
  • "One of the neighbors' discarded cigarettes must have blown into the back yard during a recent dust storm," Lopez said.
  • "We were training Gizmo to go outside to pee, but when I went to bring him in, I noticed a cigarette butt stuck to his fur.
  • We had no idea that a cigarette butt could be so dangerous to pets."

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Monday, September 11, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Monday, September 11, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Friday, September 8, 2023
Vaccine, Active ingredient, DNA, Intellectual property, Nanoparticle, Nano, Prevalence, Teva Active Pharmaceutical Ingredients, Cancer, Anesthetic, Bladder cancer, Research, Nanomedicine, Grave, Incidence, VEGF, Investment, Patient, Erythropoietin, Graves' disease, Acid, Heartburn, Viral, Conditional sentence, Growth, Antiemetic, R, API, Hyperthyroidism, Nanotechnology, Chronic kidney disease, Mouth, Antacid, Pharmaceutical industry, Fine chemical

LONDON, Sept. 8, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs

Retrieved on: 
Monday, June 12, 2023
Palonosetron, Nausea, FACP, Agency for Healthcare Research and Quality, CINV, Antiemetic, Advances in Therapy, APPA, Pharmacy, Doctor of Philosophy, Quality, GLM, Vomiting, Cancer, MD, Patient, Data, Agency, Lead author, Rare, Pharmaceutical industry, Health insurance, Pet industry, Hospital

The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.

Key Points: 
  • The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.
  • Referring to the details of the publication below, these real-world data showed that healthcare resource utilization, such as CINV-related visits were significantly lower after AKYNZEO® compared to fosaprepitant/palonosetron (APPA).
  • CINV-related healthcare costs were also statistically and/or numerically lower for patients receiving AKYZNEO® compared to APPA.
  • There remains a gap between expected and actual patient outcomes as clinicians translate trial data and clinical guidelines into practice.

Reliefband® State of Nausea Study Reveals More Than Three-Quarters of Americans Are Prevented from Enjoying Life As a Result of Regular Nausea

Retrieved on: 
Tuesday, May 16, 2023
Airsickness, Pregnancy, Travel, Motion, Wrist, Median nerve, Skiing, Anxiety, Sleep, Human, Research, Motion sickness, Brain, Hangover, Bangladesh Technical Education Board, Stomach, Mother, Vomiting, Morning sickness, Motivation, Throat, Health, FDA, Antiemetic, Mouth, Migraine, Birth control, Gasoline, Nausea

HORSHAM, Pa., May 16, 2023 /PRNewswire-PRWeb/ -- Reliefband®, an innovator in wearable technology that prevents and treats nausea and vomiting, has released its First Annual State of Nausea study. According to the survey findings, nausea is epidemic in the United States, with 73% of Americans reporting that they suffer from nausea regularly. Of those who suffer from nausea, 76% stated that their symptoms prevent them from enjoying life to the fullest.

Key Points: 
  • According to the survey findings, nausea is epidemic in the United States, with 73% of Americans reporting that they suffer from nausea regularly.
  • Of those who suffer from nausea, 76% stated that their symptoms prevent them from enjoying life to the fullest.
  • Released on National Stop Nausea Day, the study sheds light on the magnitude of the problem and its far-reaching consequences.
  • 31% of Americans reported experiencing nausea every day, 26% at least once weekly, and 16% once each month.

Trevena Reports First Quarter 2023 Results and Provides Business Update

Retrieved on: 
Monday, May 15, 2023
Epilepsy, Vomiting, Cleveland Clinic, Central nervous system, Senior, Delirium, ARTEMIS, Atrium Health Wake Forest Baptist, EMR, Trevena, PACU, CNS, Sale, Incidence, Patient, Central nervous system disease, National Medical Products Administration, Webcast, Transcranial magnetic stimulation, IND, Chronic pain, NMPA, Antiemetic, S1P, Pharmaceutical industry

OLINVYK receives Chinese regulatory approval; milestone and expected near-term commercialization provides up to $18 million of non-dilutive funding for Trevena.

Key Points: 
  • OLINVYK receives Chinese regulatory approval; milestone and expected near-term commercialization provides up to $18 million of non-dilutive funding for Trevena.
  • Jiangsu Nhwa Pharmaceutical (Nhwa) recently announced regulatory approval of OLINVYK from the National Medical Products Administration (NMPA) of China.
  • Recent Electronic Medical Records (EMR) data from the ARTEMIS study provides additional clinical support for the use of OLINVYK.
  • Cash, cash equivalents and marketable securities were $27.4 million as of March 31, 2023, which the Company believes will be sufficient to fund the Company’s operations through year-end 2023.

Reliefband Flex® Launches as Next-Generation, Water-Resistant Wearable That Offers Two Weeks of Uninterrupted Nausea Relief

Retrieved on: 
Wednesday, April 19, 2023
Pregnancy, Wrist, Median nerve, Anxiety, Telephone, Constipation, Samsung, Motion sickness, Hangover, Stomach, Flex, Vomiting, Mevalonate pathway, Nausea, Morning sickness, Apple, FDA, Somnolence, Family, Antiemetic, Lithium, Pharmaceutical industry

Available now, the water-resistant Reliefband Flex is powered by easily replaceable lithium coin batteries and delivers over 350 hours of use -- doubling the usable hours offered by the Reliefband Classic®. The Reliefband Flex joins the family of wearable Reliefband devices to deliver all-natural, drug-free prevention and treatment of nausea and vomiting associated with motion sickness, morning sickness during pregnancy, chemotherapy, anxiety, hangovers, physician-diagnosed migraines, and as an adjunct to antiemetics in treating post-operative nausea.

Key Points: 
  • The Reliefband Flex comes standard with the company's popular Flex-Fit comfort band.
  • Using available interchangeable bands and smart watch connectors, Reliefband Flex can also be seamlessly attached to an Apple or Samsung smart watch.
  • Reliefband Flex helps those who suffer from nausea live their full lives without interruption," explained Rich Ransom, President, and CEO, at Reliefband.
  • Reliefband Flex complements the company's lineup of successful anti-nausea wearables, including the water-resistant Reliefband Sport ®, Reliefband Classic ®, Reliefband Premier ®, and Reliefband 50 Hour ® (an entry-level wearable that provides an economical solution for shorter-term nausea relief).

Trevena Reports Fourth Quarter 2022 Results and Provides Business Update

Retrieved on: 
Thursday, March 30, 2023
Epilepsy, Vomiting, Male, Cleveland Clinic, Central nervous system, Senior, Delirium, ARTEMIS, Atrium Health Wake Forest Baptist, EMR, Trevena, PACU, Confusion Assessment Method, CNS, Richmond Agitation-Sedation Scale, Sale, Incidence, Data analysis, Length of stay, Patient, Central nervous system disease, Risk, Nausea, Webcast, Transcranial magnetic stimulation, Hospital, Richmond, Abdominal ultrasonography, GI, S1P, Antiemetic, Peripheral nervous system, Nursing, Pharmaceutical industry, Cryptocurrency, Electroencephalography

CHESTERBROOK, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2022 and provided an overview of its recent operational highlights.

Key Points: 
  • As reference, in pooled data for the Company’s pivotal Phase 3 studies of OLINVYK, the GI complete response rate was 46.2% (0.35mg) and 39.7% (0.50mg).
  • Analysis of respiratory data from VOLITION is not yet available, and the Company expects to report these data mid-2023.
  • In the fourth quarter of 2022, the commercial team signed contracts with three new specialty distributors that focus primarily on ambulatory surgery centers (ASCs).
  • Cash and cash equivalents were $38.3 million as of December 31, 2022, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the fourth quarter of 2023.

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia

Retrieved on: 
Tuesday, November 29, 2022
National Comprehensive Cancer Network, Liver, Degenerative disease, Kidney, Risk, Benzodiazepine, Medical Affairs Bureau, Chronic kidney disease, Serotonin syndrome, Therapy, Alprazolam, DEX, Dexamethasone, Patient, Heart, Environment, Palonosetron, Nausea, Hypersensitivity, Journal of the National Comprehensive Cancer Network, Fatigue, Respect, European Society for Medical Oncology, CINV, MEC, Constipation, Seizure, Plasma, Growth, NCCN, Weakness, University, Oncology, Capsule, Antiemetic, Midazolam, Netupitant, NEPA, Licensed practical nurse, Triazolam, Headache, Anaphylaxis, Indigestion, Erythema, ESMO, Cancer, Dysautonomia, Congress, Pharmaceutical industry, Platinum, Vaccine, CYP3A4, Vomiting

Lugano, Switzerland, November 29, 2022 - Helsinn Group (Helsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.

Key Points: 
  • Lugano, Switzerland, November 29, 2022 - Helsinn Group (Helsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.
  • Full details of the poster presentation are below:
    Dr Silvia Sebastiani, Helsinn Group Head of Medical Affairs, commented: We are pleased to present the design of this important ongoing study at the ESMO Asia congress.
  • Despite the array of effective antiemetics, CINV still represents a huge unmet need in clinical practice.
  • Available at: http://www.mascc.org/ /
    2 NCCN: National Comprehensive Cancer Network; NCCN Clinical Practice Guidelines in Oncology; Version 2.2022.